MaaT Pharma,a French oncology company, said that it has dosed the first patient in the HERACLES phase 2 trial of MaaT013, a microbiome restoration candidate, in patients with steroid-resistant acute Graft-versus-Host-Disease (SR-aGvHD). aGvHD is considered to be one of the major causes of death after an allogeneic stem cell transplant because of attack of the transplanted […]
Continue reading …
US biopharma company Bristol-Myers Squibb (BMS) has entered into a clinical collaboration with Compugen to evaluate the combination of its cancer drug Opdivo (nivolumab) with the Israeli genomics-based drug and diagnostic discovery company’s COM701 in advanced solid tumors. COM701 is being investigated by Compugen as an anti-PVRIG antibody while the cancer drug Opdivo is a […]
Continue reading …
Japanese biotech company GNI Group will end enrolment of new patients for a phase 2 liver fibrosis trial of its drug candidate F351 in China following the recommendation of an independent data monitoring committee based on the positive efficacy results achieved till date. So far, 175 out of the originally targeted 240 patients have been […]
Continue reading …
Five Prime Therapeutics and Zai Lab have dosed the first patient in a phase 3 study of bemarituzumab (FPA144) in combination with chemotherapy in patients having advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The late-stage trial named as FIGHT features advanced gastric cancer or gastroesophageal junction cancer patients who were not subjected to […]
Continue reading …
Trovagene, a California-based cancer research company, said that it has wrapped up the second dosing cohort of the Onvansertib-decitabine combination, in a phase 1b/2 acute myeloid leukemia trial. Onvansertib is said to be a highly-selective oral Polo-like Kinase 1 (PLK1) inhibitor. Designed to be orally administered, Onvansertib has a 24-hour drug half-life. According to Trovagene, […]
Continue reading …Janssen depression medication esketamine nasal spray yields mixed results in phase 3 trial
September 23, 2018 No Comment
Janssen Pharmaceutical Companies of Johnson & Johnson depression medication esketamine nasal spray did not meet expectations in a phase 3 trial in patients with treatment-resistant depression. The late-stage randomized trial evaluated two fixed doses of esketamine – 56 mg and 84 mg along with an oral antidepressant in comparison to placebo plus oral antidepressant. Janssen […]
Continue reading …Oncternal begins phase 1b trial of breast cancer drug cirmtuzumab and paclitaxel combo
September 13, 2018 No Comment
US oncology company Oncternal Therapeutics said that the first patient enrolled in a phase 1b trial of its investigational breast cancer drug cirmtuzumab in combination with paclitaxel, a standard-of-care chemotherapy drug, has been dosed. The phase 1b trial is evaluating the anti-ROR1 monoclonal antibody cirmtuzumab combination with paclitaxel, in breast cancer patients who are negative […]
Continue reading …Humira biosimilar Cyltezo meets objective in phase 3 plaque psoriasis trial
September 13, 2018 No Comment
German pharma company Boehringer Ingelheim said that Cyltezo, a biosimilar to AbbVie psoriasis drug Humira, achieved clinical equivalence to the reference product in a phase 3 trial in patients with moderate-to-severe chronic plaque psoriasis. Cyltezo succeeded in the NCT 02850965 phase 3 trial by not showing any clinically meaningful differences in efficacy, safety and immunogenicity […]
Continue reading …
Irish biopharma company Alkermes said that it has expanded an ongoing phase 1 trial for its immuno oncology drug ALKS 4230 to assess its safety and anti-tumor activity in combination with Merck’s PD-1 inhibitor KEYTRUDA (pembrolizumab) in advanced solid tumors. According to Alkermes, ALKS 4230 is an engineered fusion protein which selectively binds and signals […]
Continue reading …PvP Biologics initiates Kuma062 human trials for celiac disease treatment
September 8, 2018 No Comment
PvP Biologics, a US pharma company, has initiated two phase 1 clinical trials for Kuma062 to evaluate the recombinant enzyme for celiac disease treatment. According to PvP Biologics, Kuma062 has been designed to be active under acidic stomach conditions and it specifically targets the parts of gluten that are behind the autoimmune reaction causing celiac […]
Continue reading …
Business News Today
- CSV Southern Ocean bags new contract for works in India
- Innovent Biologics begins phase 1 trial of IBI315 in solid malignancies
- Tru Kids Brands to open first Toys”R”Us store in US at Paramus, NJ
- TA Associates invests in Taiwanese tea brand Gong cha
- Wintershall Dea Norge makes minor oil discovery in North Sea at PL 896
- Global Blood Therapeutics bags Oxbryta FDA approval for sickle cell disease
- Pioneer Transformers acquires transformer products manufacturer Power Partners
- Gsport creates cohesive bandages for human and animal patients
- Kirkland Lake Gold to acquire Detour Lake gold mine owner Detour Gold
- Gunvor signs agreement with Commonwealth LNG export project
